RUNX2, a master transcription factor originally characterised for its central role in bone development, has emerged as a pivotal regulator of cancer cell dissemination and colonisation. Aberrant ...

Researchers uncover how a key protein controls cranial base growth, revealing complex pathways that could inform future therapies The cranial base, which forms the floor of the skull, is essential for ...

The runx2 master transcription factor functions differently in chondrocytes and osteoblasts, two key cells in bone formation, scientists report. This research has taken a major step forward in ...

Researchers have identified the role of transcription factors Runx1 and Runx2 in the inhibition of fibrosis, the abnormal build-up of connective tissue with severe hematopoietic defects, in the bone ...

A research group has revealed that transcription factors RUNX2 and BHLHE40 play crucial roles in inducing T cells involved in Crohn's disease. Crohn's disease is an intractable disorder characterized ...

IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKCι inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC). This is an ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target tumors. Despite their initial clinical success, many patients eventually ...

The research group led by Drs. Mitsuru Arase, Mari Murakami, and Prof. Kiyoshi Takeda (Graduate School of Medicine/ Immunology Frontier Research Center at The University of Osaka) revealed that ...

Researchers from Columbia University Irving Medical Center and collaborators applied unbiased scRNA-seq to study Lepr expression in lung mesenchymal cells. To do that, they used a Lepr(creERT2) mouse ...

Researchers from Osaka University identify genes that contribute to the hematopoietic stem cell niche by inhibiting fibrosis in the bone marrow Osaka, Japan – In your home, storing books on a ...